Last updated: September 1, 2026
Nitrofurantoin macrocrystals is a mature, low-cost generic antibiotic with durable clinical demand but limited pharmaceutical pricing power. U.S. revenue is concentrated in generic capsules, mainly nitrofurantoin macrocrystals 25 mg, 50 mg, and 100 mg, plus the related nitrofurantoin monohydrate/macrocrystals product sold as Macrobid. The product has no meaningful remaining innovator exclusivity or patent barrier. Financial performance depends on prescription volume, reimbursement, manufacturing reliability, API costs, and the number of active suppliers rather than on premium pricing.
Nitrofurantoin Macrocrystalline Market Dynamics and Financial Trajectory
What is nitrofurantoin macrocrystals and how is it marketed?
Nitrofurantoin macrocrystals is an oral nitrofuran antibacterial used primarily to treat acute uncomplicated urinary tract infections caused by susceptible organisms. In the United States, macrocrystalline products are marketed as:
| Product |
Active ingredient |
Common strengths |
Primary use |
| Macrodantin |
Nitrofurantoin macrocrystals |
25 mg, 50 mg, 100 mg |
Treatment and suppression of urinary tract infection |
| Generic nitrofurantoin macrocrystals |
Nitrofurantoin macrocrystals |
25 mg, 50 mg, 100 mg |
Treatment of urinary tract infection |
| Macrobid |
Nitrofurantoin monohydrate/macrocrystals |
100 mg |
Acute uncomplicated cystitis |
Macrobid is a distinct dosage-form combination containing 25% nitrofurantoin macrocrystals and 75% nitrofurantoin monohydrate. It is not interchangeable with a 100 mg capsule of nitrofurantoin macrocrystals solely on the basis of labeled strength. The products have different release characteristics and labeling requirements. [1]
Nitrofurantoin is generally used for lower urinary tract infection and is not appropriate for suspected pyelonephritis because tissue and renal parenchymal concentrations are inadequate. The FDA labeling also limits use in patients with materially impaired renal function and warns of pulmonary, hepatic, neurologic, and hematologic adverse reactions. [1]
What is the FDA regulatory status of nitrofurantoin macrocrystals?
Nitrofurantoin macrocrystals is an FDA-approved immediate-release prescription capsule. It is an established small-molecule product approved through abbreviated and legacy regulatory pathways rather than through a modern new drug development program.
Key regulatory characteristics include:
| Regulatory factor |
Status |
| FDA pathway |
Generic and legacy NDA products |
| Prescription status |
Prescription only |
| Dosage form |
Oral capsule |
| Reference products |
Macrodantin and related nitrofurantoin products |
| Biosimilar pathway |
Not applicable |
| FDA exclusivity |
No meaningful current market exclusivity |
| OTC conversion |
None |
| Orange Book relevance |
Product-specific patents and exclusivity, if listed, are the relevant measures |
The product does not face biosimilar competition because nitrofurantoin is a chemically synthesized small molecule. Competition occurs through ANDA-approved generic products.
When did nitrofurantoin macrocrystals lose patent and exclusivity protection?
The original patent and regulatory exclusivity periods for nitrofurantoin products expired decades ago. Current commercial risk is therefore unrelated to a pending basic-composition patent expiration.
The Orange Book should be used to confirm the current listing status for each reference product and strength. A product may remain listed in the Orange Book even when no enforceable commercial patent barrier remains. The absence of a listed patent does not eliminate all possible litigation risk, but it removes the principal FDA-linked barrier to ANDA approval. [2]
Patent estate assessment
| Patent category |
Current commercial relevance |
| Nitrofurantoin composition patents |
Expired |
| Macrodantin basic formulation patents |
Expired or commercially obsolete |
| Macrobid formulation patents |
Historical protection; no current broad barrier to generic competition |
| Method-of-use patents |
Limited value because UTI treatment is long established and generic labeling is broad |
| Manufacturing patents |
Potentially relevant to cost and supply, but generally do not block ordinary generic entry |
| Pediatric or dosing exclusivity |
No material current exclusivity |
| Orphan-drug exclusivity |
Not applicable |
The remaining intellectual-property value is mainly operational. A manufacturer may protect a specific process, impurity-control method, capsule configuration, or supply arrangement, but these rights are unlikely to support branded pricing comparable with patent-protected products.
How many patents cover nitrofurantoin macrocrystals?
No active patent estate appears to provide broad, commercially meaningful exclusivity for nitrofurantoin macrocrystals in the U.S. market. Historical patents covered the active ingredient, formulations, and related delivery characteristics, but the market has operated as a generic category for many years.
The relevant distinction is between:
- Patents listed for an FDA reference product.
- Patents that remain legally enforceable.
- Patents that can delay ANDA approval.
- Patents that can support a product-level price premium.
For nitrofurantoin macrocrystals, those categories do not currently align around a meaningful barrier. A patent that covers a manufacturing step may remain relevant to a particular applicant without preventing other companies from selling an independently manufactured product.
Which companies manufacture or market nitrofurantoin macrocrystals?
The U.S. market has included multiple generic manufacturers and marketers over time. Availability changes as companies enter, exit, transfer abbreviated applications, or suspend production. Manufacturers and labelers appearing in U.S. commercial channels have included organizations such as:
- Hikma Pharmaceuticals
- Rising Pharmaceuticals
- ANI Pharmaceuticals
- Amneal Pharmaceuticals
- Teva Pharmaceuticals
- Mylan, now part of Viatris
- Sun Pharmaceutical Industries
- Apotex
- Nostrum Laboratories
- Alvogen and related generic entities
The precise active supplier group varies by strength, package size, wholesaler, and date. FDA Drug Shortages and Drugs@FDA records are more reliable for current supply status than historical commercial directories. [3,4]
Macrodantin’s commercial position has been weaker than the generic category. Macrobid has retained greater brand recognition because its monohydrate/macrocrystals formulation is widely prescribed and historically supported by stronger commercial distribution. Neither brand has a durable patent-based pricing advantage.
What drives demand for nitrofurantoin macrocrystals?
Demand is linked to the high incidence of uncomplicated urinary tract infection, especially cystitis in women. Nitrofurantoin remains a preferred or recommended oral option in major clinical guidelines when the infection is limited to the lower urinary tract and the organism is susceptible. [5,6]
The main demand drivers are:
- High UTI incidence and recurrence.
- Continued use of antibiotic stewardship protocols.
- Favorable resistance profile against common uropathogens in many markets.
- Low acquisition cost.
- Oral administration.
- Established physician familiarity.
- Limited suitability of some competing antibiotics because of resistance or safety concerns.
Demand is constrained by renal-function restrictions, intolerance, pulmonary and hepatic safety concerns, and limited utility for upper urinary tract infection. It is also unsuitable for certain organisms and complicated infections requiring tissue penetration.
Competitive products
Nitrofurantoin competes with:
- Trimethoprim/sulfamethoxazole.
- Fosfomycin tromethamine.
- Fluoroquinolones.
- Oral beta-lactams, including cephalexin and amoxicillin/clavulanate.
- Other region-specific antibiotics.
Nitrofurantoin benefits from antibiotic stewardship because fluoroquinolones are often avoided for uncomplicated cystitis when safer alternatives are available. Fosfomycin is a close clinical competitor but is frequently used as a single-dose product and can carry a higher acquisition cost. Trimethoprim/sulfamethoxazole remains important but is constrained by local resistance levels and patient-specific contraindications.
How does nitrofurantoin macrocrystals compare with Macrobid?
Macrobid and nitrofurantoin macrocrystals share the same antibacterial ingredient but are different products.
| Attribute |
Nitrofurantoin macrocrystals |
Macrobid |
| Formulation |
Macrocrystalline nitrofurantoin |
Nitrofurantoin monohydrate/macrocrystals |
| Typical U.S. strength |
25 mg, 50 mg, 100 mg |
100 mg |
| Dosing pattern |
Commonly four times daily under product labeling |
Commonly twice daily under product labeling |
| Commercial status |
Predominantly generic |
Brand plus generic equivalents |
| Differentiation |
Lower manufacturing and acquisition cost |
Dosing convenience and established brand recognition |
| Patent position |
Mature generic category |
Historical formulation protection; no broad current barrier |
| Revenue potential |
Low price, volume-driven |
Higher possible unit price, but generic pressure remains |
The primary commercial advantage of Macrobid is dosing convenience. The principal weakness is the availability of generic equivalents, which limits sustainable price premiums.
What is the current pricing and revenue outlook?
Public companies generally do not report nitrofurantoin macrocrystals revenue as a separate product line. Reported revenue is usually grouped within broad generic portfolios. As a result, reliable product-level revenue, market share, and EBITDA figures are not publicly available for the full U.S. market.
The financial trajectory is best characterized as follows:
| Period |
Financial condition |
| Before generic penetration |
Higher brand pricing and stronger product-level margins |
| Early generic entry |
Rapid price erosion and share transfer to generic suppliers |
| Mature generic phase |
Low unit prices, stable prescription demand, modest portfolio contribution |
| Supply-constrained periods |
Temporary price increases and margin expansion for available suppliers |
| Long-term outlook |
Volume-stable, price-sensitive, operationally driven |
Revenue growth is unlikely to come from price increases under ordinary competitive conditions. Growth opportunities are more likely to arise from:
- Additional approved suppliers.
- Contract manufacturing.
- Hospital and retail formulary expansion.
- Improved availability during competitor shortages.
- Portfolio bundling with other anti-infectives.
- Geographic expansion outside the U.S.
- Higher-margin packaging or private-label arrangements.
For a generic manufacturer, the product can remain economically useful despite low pricing because development costs are modest, clinical demand is recurring, and the capsule technology is established. The risk is that low prices may discourage redundant manufacturing capacity, increasing exposure to temporary shortages.
What generic entry risks exist for nitrofurantoin macrocrystals?
Generic entry risk is effectively mature rather than prospective. The main commercial threat is not a future first ANDA launch. It is continued competition among existing or reactivated suppliers.
The key risks are:
- Price compression from additional ANDA holders.
- Wholesaler substitution toward the lowest-cost supplier.
- Contract loss in retail, Medicaid, managed care, or hospital channels.
- API or excipient shortages.
- Manufacturing observations or regulatory actions.
- Product discontinuation caused by low margins.
- Substitution toward Macrobid-equivalent products.
- Therapeutic substitution with fosfomycin or trimethoprim/sulfamethoxazole.
The strongest supplier position generally belongs to a company with reliable API sourcing, multiple approved strengths, adequate packaging capacity, and established wholesaler access. A single approved strength has less commercial resilience than a full 25 mg, 50 mg, and 100 mg portfolio.
What manufacturing and intellectual-property barriers affect the market?
Nitrofurantoin macrocrystals has limited legal barriers but meaningful manufacturing requirements. Quality control must address particle-size distribution, assay, dissolution, impurities, content uniformity, and capsule-fill consistency. Macrocrystalline properties can influence dissolution and tolerability, making process control commercially relevant even when the formulation is old.
Manufacturing risks include:
- Dependence on a limited number of API sources.
- Variability in particle-size distribution.
- Batch failures involving dissolution or content uniformity.
- Packaging and capsule-shell supply constraints.
- FDA inspection findings.
- Low-margin economics that reduce supplier redundancy.
- Difficulty maintaining multiple strengths at low annual volumes.
These factors can create temporary supply advantages without producing durable exclusivity.
What patent litigation and Paragraph IV activity affect nitrofurantoin macrocrystals?
There is no prominent current Paragraph IV litigation pattern comparable with newer specialty medicines. Any historic Paragraph IV disputes associated with Macrobid or related nitrofurantoin products have not created a continuing market barrier for the mature generic category.
For current diligence, the relevant checks are:
- FDA Orange Book patent listings for the applicable reference product.
- FDA Paragraph IV certification notices.
- ANDA approval and tentative-approval history.
- Federal court docket activity involving reference-product sponsors and ANDA applicants.
- Product discontinuation and shortage records.
The practical litigation risk is low relative to the commercial risks of price competition and manufacturing disruption.
What is the international market outlook for nitrofurantoin macrocrystals?
Nitrofurantoin is marketed internationally under different formulation names and regulatory standards. The commercial opportunity is strongest where:
- UTI incidence is high.
- Antibiotic stewardship discourages fluoroquinolone use.
- Generic procurement is established.
- Local resistance supports nitrofurantoin use.
- Regulatory approval for the relevant formulation is available.
The principal geographic constraint is formulation-specific registration. Approval of nitrofurantoin macrocrystals does not automatically authorize sale of monohydrate/macrocrystals or other modified formulations. Country-level differences in renal-function labeling, prescription controls, procurement systems, and antimicrobial guidelines also affect demand.
Emerging markets may offer higher volume but lower prices. Developed markets generally provide stronger reimbursement infrastructure but more aggressive generic substitution.
What is the financial trajectory for manufacturers?
For manufacturers, nitrofurantoin macrocrystals is a defensive generic rather than a growth asset. Its value comes from recurring demand and portfolio breadth.
Base case
Volume remains broadly stable, while average selling prices decline gradually. Gross margin stays positive for efficient suppliers with scale and dependable API access.
Upside case
A competitor exits, a shortage develops, or a manufacturer secures a large institutional contract. Available suppliers may obtain temporary price improvement and higher utilization.
Downside case
Multiple suppliers compete aggressively, reimbursement falls, or API and compliance costs rise. The product becomes economically unattractive despite stable prescription demand.
The product is unlikely to generate material standalone revenue for a large pharmaceutical company. It can still contribute to a generic portfolio by filling a high-volume, low-development-cost category and supporting customer relationships across antibiotics.
What is the market strength of nitrofurantoin macrocrystals?
The patent estate is weak because protection is expired. The commercial product position is stronger than the legal position because clinical demand is durable and the drug remains guideline-supported for uncomplicated cystitis.
| Strength factor |
Assessment |
| Patent protection |
Very weak |
| Regulatory exclusivity |
None of practical significance |
| Clinical demand |
Durable |
| Brand differentiation |
Limited for macrocrystals; higher for Macrobid |
| Pricing power |
Low |
| Generic competition |
High |
| Supply-chain sensitivity |
Moderate to high |
| Biosimilar exposure |
None |
| Long-term revenue growth |
Low |
| Portfolio utility |
Moderate for generic manufacturers |
Key Takeaways
- Nitrofurantoin macrocrystals is a mature generic antibiotic with stable demand and low pricing power.
- Macrodantin and generic macrocrystalline capsules are distinct from Macrobid, which contains nitrofurantoin monohydrate/macrocrystals.
- Original patents and exclusivity protections are expired; no broad current patent barrier is expected to delay generic competition.
- The principal market drivers are UTI incidence, antimicrobial stewardship, resistance patterns, and formulary preference.
- Product-level revenue is generally not disclosed by manufacturers, making precise market-size estimates unreliable.
- Financial performance depends on volume, supplier concentration, API access, manufacturing quality, and reimbursement.
- Paragraph IV and patent-litigation risk is low compared with supply and price-competition risk.
- The product is a defensive portfolio asset, not a likely source of pharmaceutical revenue growth.
FAQs About Nitrofurantoin Macrocrystals Market Economics
Can nitrofurantoin macrocrystals support premium pricing?
Usually not. Premium pricing may occur temporarily during shortages or supplier exits, but the mature generic category limits sustained price differentiation.
Is Macrobid financially stronger than nitrofurantoin macrocrystals?
Macrobid has greater brand recognition and dosing convenience, but generic monohydrate/macrocrystals products constrain its long-term pricing power. Macrocrystalline nitrofurantoin is generally more exposed to commodity generic pricing.
Does nitrofurantoin macrocrystals have biosimilar competition?
No. Nitrofurantoin is a chemically synthesized small molecule, so competition occurs through generic drug applications rather than biosimilar applications.
What would most likely increase nitrofurantoin macrocrystals revenue?
A supplier exit, shortage, institutional contract, geographic expansion, or broader portfolio placement would be more likely to increase revenue than a patent-based price increase.
Is nitrofurantoin macrocrystals vulnerable to therapeutic substitution?
Yes. Fosfomycin, trimethoprim/sulfamethoxazole, and selected beta-lactams can substitute clinically depending on susceptibility, renal function, treatment setting, local guidelines, and patient factors.
References
- U.S. Food and Drug Administration. (2023). Macrodantin (nitrofurantoin macrocrystals) capsules: Prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
- U.S. Food and Drug Administration. (2024). FDA drug shortages database.
- Gupta, K., Hooton, T. M., Naber, K. G., et al. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 52(5), e103-e120.
- Infectious Diseases Society of America. (2011). International clinical practice guidelines for acute uncomplicated cystitis and pyelonephritis in women. [5]
